The Industry That Studies Human Performance Has a Blind Spot. And It Is Itself.

Across nearly two decades working in clinical research and life sciences, I have sat in a lot of rooms where important decisions were being made. Decisions about trial design. About patient safety. About regulatory submissions. About whether a compound had enough evidence to move forward, or whether the data was telling us something we did not want to hear.

In all of those rooms, across all of those years, I cannot recall a single conversation about the cognitive state of the people making those decisions.

Not one.

We talked about methodology. We talked about statistical power and confidence intervals and risk-benefit profiles. We talked about timelines and budgets and stakeholder expectations. We did not talk about whether the researchers who had been working sixteen-hour days for weeks were still capable of the quality of thinking those decisions required.

I find that extraordinary. And I find it worth saying out loud.

The Profession That Forgot to Study Itself

Healthcare and life sciences are industries built on the rigorous study of human performance and human limitation. We know, in extraordinary detail, how stress affects the body. How sleep deprivation impairs judgement. How cognitive load degrades the quality of complex reasoning. We have published thousands of papers on it.

And yet the culture of these industries, the hours, the pressure, the expectation of relentless output from highly trained professionals, operates as though none of that science applies to the people doing the work.

The research on decision fatigue in clinical settings is sobering. Studies have shown that the time of day a physician makes a decision significantly affects the outcome. Prescribing patterns change across the course of a working day in ways that are not clinically justified. Screening rates for certain conditions drop measurably as the day progresses. Surgical complication rates vary depending on where a procedure falls in the operating schedule. These are not small effects. These are documented, peer-reviewed findings about how cognitive depletion affects some of the most consequential decisions in human life.

And they are almost entirely absent from the conversation about how we support the professionals responsible for those decisions.

“We have built entire systems to protect patients from human error. We have built almost nothing to protect the humans from the conditions that cause it.”

What Decision Fatigue Looks Like in Our World

In clinical research specifically, the cognitive demands are not just high. They are sustained, complex, and cumulative in ways that make decision fatigue particularly acute.

A clinical trial manager is simultaneously holding the protocol, the patient safety data, the site performance metrics, the regulatory requirements, and the sponsor expectations in their head, across months and sometimes years. A principal investigator is making clinical and scientific judgement calls while also navigating the operational realities of running a site. A biotech founder is evaluating trial data while managing investor relationships, team morale, regulatory strategy, and the very real possibility that the results will not support the hypothesis they have staked their company on.

These are not nine-to-five decision loads. They are relentless, layered, and emotionally weighted in ways that compound the biological cost of sustained cognitive work.

The mechanism is the same one Shawn Watson, our Chief Science Officer at Numin, has written about in detail. Every decision generates glutamate as a byproduct of neural activity. Under sustained cognitive demand, that glutamate accumulates in the prefrontal cortex faster than the brain can clear it. The result is a progressive degradation in decision quality that has nothing to do with intelligence or commitment and everything to do with biology. Your brain is not broken. It is simply running up against a physiological limit that our industry systematically ignores.

The Particular Cost in Biotech and Pharma

In the broader biotech and pharmaceutical world, the stakes attached to fatigued decision-making are rarely about a single patient or a single outcome. They scale.

A go or no-go decision on a clinical programme made at the end of an exhausting board meeting can determine whether a potential treatment reaches the patients who need it, or whether years of work and hundreds of millions of dollars are redirected or abandoned. A regulatory submission reviewed under deadline pressure, with team members running on too little sleep and too many consecutive hours of detailed analytical work, carries real risk of errors that affect approval timelines. A site selection decision made by someone operating at the far end of their cognitive capacity looks different from the same decision made by the same person at their sharpest.

We accept this as the cost of working in a demanding industry. We should be questioning whether it has to be.

“The cost of decision fatigue in our industry is not just personal. It is scientific. It is clinical. It is, ultimately, human.”

Why This Matters More Than We Admit

I want to be careful here, because I am not suggesting that the professionals in our industry are making bad decisions or that the systems we have built are failing. I am suggesting something more uncomfortable: that we are routinely asking brilliant, dedicated people to make critical decisions in conditions that we know, from our own published research, impair the quality of complex reasoning.

And we have normalised it so thoroughly that we do not even see it as a problem worth solving.

The junior researcher who stays until midnight to meet a data lock deadline. The clinical director who takes twelve back-to-back calls on the day a protocol deviation needs to be adjudicated. The founder who has not had a full night of sleep in three months and is about to present interim results to a board that will determine the company’s next funding round. These are not edge cases. These are the conditions under which our industry routinely operates.

If a patient were making a treatment decision under those conditions, we would consider it a safeguarding concern. When a professional is, we call it dedication.

What We Can Actually Do About It

There is no single solution to a problem this structural, and I am not going to pretend there is. Building organisations that genuinely protect cognitive performance requires cultural change, leadership commitment, and a willingness to measure things that are currently invisible.

But there are practical starting points, and they begin with taking the biology seriously.

Protect decision windows. The most cognitively demanding work and the most consequential decisions should, wherever possible, be scheduled for the periods when decision quality is highest. For most people, that means earlier in the day, before the glutamate has accumulated and the cognitive clarity has started to thin.

Name the load. In team environments, creating language around cognitive fatigue, the way we now have language around emotional fatigue and burnout, allows people to signal when they are not at their best without it feeling like a professional failing. A culture that can say we are asking too much of fatigued brains right now is one that makes fewer preventable errors.

Support the biology, not just the behaviour. Structural interventions matter, but so does the physiological support that helps the brain sustain performance under genuine demand. Sleep, exercise, and nutrition are the foundations. Beyond that, there is a growing body of evidence for targeted nutritional support that addresses the specific mechanisms of cognitive fatigue at a biological level.

This is precisely what we set out to do with Numin. We did not build a stimulant. We did not build something that masks fatigue or artificially pushes through it. We built a clinically tested formula designed to support the brain’s own glutamate clearance pathways, replenish the neurotransmitters depleted by sustained cognitive demand, and protect the neurons doing the work. It was tested in a rigorous, peer-reviewed clinical trial specifically because we knew our audience would, rightly, demand nothing less.

If you work in an industry where decisions have consequences, and you are honest with yourself about the conditions under which you are routinely making them, Numin was built with you in mind as much as anyone.

A Different Kind of Performance Culture

The industries I have spent my career in are full of people who are deeply motivated by outcomes that matter. Treatments that reach patients. Trials that produce answers. Companies that bring something genuinely new into the world. That motivation is one of the things I respect most about this field.

But motivation is not a substitute for cognitive capacity. Caring deeply about your work does not protect your prefrontal cortex from the physiological effects of sustained decision load. Dedication is not a biological shield.

The most effective professionals I have known over the course of my career are not the ones who push hardest regardless of cost. They are the ones who understand their own limits well enough to work within them, protect them, and support them with the same rigour they bring to everything else.

That is not a soft idea. That is performance science. And it is long overdue in the industries that should know it best.